Rhythm Pharmaceuticals, Inc. (RYTM) Covered Calls

You can sell covered calls on Rhythm Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RYTM (prices last updated Fri 4:16 PM ET):

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
63.76 +0.79 63.26 68.00 356K - 4.0
Covered Calls For Rhythm Pharmaceuticals, Inc. (RYTM)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 16 65 1.95 66.05 -1.6% -26.5%
Jun 20 65 2.50 65.50 -0.8% -5.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.